Cost utility in second-line metastatic breast cancer.
Berdeaux
G
G
Hurteloup
P
P
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine